These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35162752)

  • 21. Cluster of SARS-CoV-2 Gamma Variant Infections, Parintins, Brazil, March 2021.
    da Silva JF; Esteves RJ; Siza C; Soares EP; Ramos TC; Campelo EC; da Costa CF; de Alencar LC; Cavalcante RP; Florêncio CR; Mattos TP; Bonecini-Almeida MG; Silva-Flannery L; Marston BJ; Morgan J; Plucinski M; Naveca F;
    Emerg Infect Dis; 2022 Jan; 28(1):262-264. PubMed ID: 34856111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resolving the enigma of Iquitos and Manaus: A modeling analysis of multiple COVID-19 epidemic waves in two Amazonian cities.
    He D; Lin L; Artzy-Randrup Y; Demirhan H; Cowling BJ; Stone L
    Proc Natl Acad Sci U S A; 2023 Mar; 120(10):e2211422120. PubMed ID: 36848558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil.
    Fintelman-Rodrigues N; da Silva APD; Dos Santos MC; Saraiva FB; Ferreira MA; Gesto J; Rodrigues DAS; Vale AM; de Azevedo IG; Soares VC; Jiang H; Tan H; Tschoeke DA; Sacramento CQ; Bozza FA; Morel CM; Bozza PT; Souza TML
    Emerg Infect Dis; 2021 May; 27(5):1446-1453. PubMed ID: 33797393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.
    Cegolon L; Magnano G; Negro C; Larese Filon F;
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515237
    [No Abstract]   [Full Text] [Related]  

  • 25. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses.
    Torresi J; Edeling MA; Nolan T; Godfrey DI
    Front Immunol; 2022; 13():914167. PubMed ID: 35911696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19.
    Peghin M; Bouza E; Fabris M; De Martino M; Palese A; Bontempo G; Graziano E; Gerussi V; Bressan V; Sartor A; Isola M; Tascini C; Curcio F
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2597-2604. PubMed ID: 34378086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [COVID-19 recurrence due to reinfection with SARS-CoV-2 in a hemodialysis patient: there and back again].
    Vigotti FN; Bianco S; Alfieri V; Bilucaglia D; Motta D; Pignataro A; Timbaldi M; Torta E; Cesano G
    G Ital Nefrol; 2022 Apr; 39(2):. PubMed ID: 35471003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
    Nordström P; Ballin M; Nordström A
    Lancet Infect Dis; 2022 Jun; 22(6):781-790. PubMed ID: 35366962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal study of humoral immunity against SARS-CoV-2 of health professionals in Brazil: the impact of booster dose and reinfection on antibody dynamics.
    Franco-Luiz APM; Fernandes NMGS; Silva TBS; Bernardes WPOS; Westin MR; Santos TG; Fernandes GDR; Simões TC; Silva EFE; Gava SG; Alves BM; de Carvalho Melo M; da Silva-Pereira RA; Alves PA; Fonseca CT
    Front Immunol; 2023; 14():1220600. PubMed ID: 37520570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
    COVID-19 Cumulative Infection Collaborators
    Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England.
    Mensah AA; Campbell H; Stowe J; Seghezzo G; Simmons R; Lacy J; Bukasa A; O'Boyle S; Ramsay ME; Brown K; Ladhani SN
    Lancet Child Adolesc Health; 2022 Jun; 6(6):384-392. PubMed ID: 35358491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England.
    Jeffery-Smith A; Rowland TAJ; Patel M; Whitaker H; Iyanger N; Williams SV; Giddings R; Thompson L; Zavala M; Aiano F; Ellis J; Lackenby A; Höschler K; Brown K; Ramsay ME; Gopal R; Chow JY; Ladhani SN; Zambon M
    Lancet Healthy Longev; 2021 Dec; 2(12):e811-e819. PubMed ID: 34873592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reinfection rate in a cohort of healthcare workers over 2 years of the COVID-19 pandemic.
    Guedes AR; Oliveira MS; Tavares BM; Luna-Muschi A; Lazari CDS; Montal AC; de Faria E; Maia FL; Barboza ADS; Leme MD; Tomazini FM; Costa SF; Levin AS
    Sci Rep; 2023 Jan; 13(1):712. PubMed ID: 36639411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection.
    Beppu H; Ogawa T; Ishikane M; Kawanishi T; Fukuda T; Sato L; Matsunaga A; Maeda K; Katagiri D; Ishizaka Y; Mitsuya H; Ohmagari N; Yasui F; Kohara M; Kikuchi K; Wakai S
    CEN Case Rep; 2022 Nov; 11(4):422-427. PubMed ID: 35266095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes associated with SARS-CoV-2 reinfection in individuals with natural and hybrid immunity.
    Suleyman G; Fadel R; Patel K; Shadid AM; Stuart HBC; Kattula M; Janis A; Maki M; Chao S; Alangaden G; Brar I
    J Infect Public Health; 2023 Aug; 16(8):1262-1268. PubMed ID: 37302273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant.
    Coutinho RM; Marquitti FMD; Ferreira LS; Borges ME; da Silva RLP; Canton O; Portella TP; Poloni S; Franco C; Plucinski MM; Lessa FC; da Silva AAM; Kraenkel RA; de Sousa Mascena Veras MA; Prado PI
    Commun Med (Lond); 2021; 1():48. PubMed ID: 35602219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers.
    Adrielle Dos Santos L; Filho PGG; Silva AMF; Santos JVG; Santos DS; Aquino MM; de Jesus RM; Almeida MLD; da Silva JS; Altmann DM; Boyton RJ; Alves Dos Santos C; Santos CNO; Alves JC; Santos IL; Magalhães LS; Belitardo EMMA; Rocha DJPG; Almeida JPP; Pacheco LGC; Aguiar ERGR; Campos GS; Sardi SI; Carvalho RH; de Jesus AR; Rezende KF; de Almeida RP
    J Infect; 2021 Mar; 82(3):399-406. PubMed ID: 33589297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis.
    Nguyen NN; Nguyen YN; Hoang VT; Million M; Gautret P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 reinfection and COVID-19 severity.
    Nguyen NN; Houhamdi L; Hoang VT; Delerce J; Delorme L; Colson P; Brouqui P; Fournier PE; Raoult D; Gautret P
    Emerg Microbes Infect; 2022 Dec; 11(1):894-901. PubMed ID: 35264078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.